Loading...
Loading...
Pharmaceutical Importer Β· #8 buyer for Exemestane Β· $250.0K import value Β· 5 shipments Β· UNITED STATES Β· DGFT Verified
Zydus Pharmaceuticals USA Inc is the #8 importer of Exemestane from India with $250.0K in import value and 5 verified shipments. Zydus Pharmaceuticals USA Inc holds a 1.7% market share in Exemestane imports based in UNITED STATES. Overall, Zydus Pharmaceuticals USA Inc imports 5 pharmaceutical products worth $1.6M across 4 therapeutic categories.

| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| INTAS PHARMACEUTICALS LIMITED | $4.5M | 260 | 21 |
| MSN LABORATORIES PRIVATE LIMITED | $1.7M | 34 | 1 |
| EUGIA PHARMA SPECIALITIES LIMITED | $1.4M | 27 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | $900.0K | 18 | 4 |
| CIPLA LIMITED | $800.0K | 16 | 3 |
| TITAN LABORATORIES PRIVATE LIMITED | $500.0K | 10 | 1 |
| INTAS PHARMACEUTICALS LTD | $355.9K | 13 | 4 |
| ZYDUS LIFESCIENCES LIMITED | $300.0K | 6 | 1 |
| CADILA HEALTHCARE LIMITED | $200.0K | 4 | 1 |
| JODAS EXPOIM PRIVATE LIMITED | $136.6K | 6 | 1 |
India's top Exemestane suppliers include INTAS PHARMACEUTICALS LIMITED, MSN LABORATORIES PRIVATE LIMITED, EUGIA PHARMA SPECIALITIES LIMITED. These companies represent the primary source of Exemestane exports from India, serving buyers like Zydus Pharmaceuticals USA Inc in UNITED STATES and other global markets.
Buyers ranked immediately above and below #8 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 13 | ACCORD UK | UNITED KINGDOM | $281.6K | 7 | $40.2K |
| 15 | AUROLOGISTICS LLC, (AUROBINDO PHARM | UNITED STATES | $255.5K | 9 | $28.4K |
| 8 | ZYDUS PHARMACEUTICALS USA INC β | UNITED STATES | $250.0K | 5 | $50.0K |
| 10 | M P L | UNITED KINGDOM | $200.0K | 4 | $50.0K |
What Zydus Pharmaceuticals USA Inc and other importers must comply with to import Exemestane from India
U.S. Food and Drug Administration (FDA)
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10β18 months for ANDA approval
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
India exported $5.1M worth of Exemestane through 1,533 shipments from 87 suppliers to 57 countries, serving 196 buyers globally. Zydus Pharmaceuticals USA Inc imports $250.0K of this total, accounting for 1.7% of India's Exemestane exports with 5 shipments from UNITED STATES.
Zydus Pharmaceuticals USA Inc's average Exemestane order value is $50.0K per consignment, based on 5 shipments totaling $250.0K. Zydus Pharmaceuticals USA Inc is based in UNITED STATES and ranks #8 among all Exemestane importers from India by value.
Top Indian Exemestane suppliers include INTAS PHARMACEUTICALS LIMITED ($4.5M), MSN LABORATORIES PRIVATE LIMITED ($1.7M), EUGIA PHARMA SPECIALITIES LIMITED ($1.4M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($900.0K), CIPLA LIMITED ($800.0K). These companies represent the primary source of Exemestane exports from India.
Zydus Pharmaceuticals USA Inc ranks #8 among 196 Exemestane importers from India with a 1.7% market share. The top 3 importers are CARDINAL HEALTH ($800.0K), BROCACEF NL HUB ($699.9K), FIEGE HEALTHCARE LOGISTICS GMBH ($604.5K). Zydus Pharmaceuticals USA Inc processed 5 shipments from UNITED STATES.
Zydus Pharmaceuticals USA Inc imports 5 products worth $1.6M. Beyond Exemestane, top products include Doxycycline, Diltiazem, Methotrexate, Atenolol. View the complete Zydus Pharmaceuticals USA Inc profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Exemestane β including regulatory updates, trade policy changes, and competitive landscape analysis β will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify import regulations and drug registration requirements with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records β the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access order-level details, pricing data, supplier connections, and competitive analysis for Zydus Pharmaceuticals USA Inc's Exemestane imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Pharmaceuticals USA Inc
Full Company Profile β
5 products Β· $1.6M total trade Β· 4 categories
| 7 |
| AUROBINDO PHARMA USA INC |
| UNITED STATES |
| $150.0K |
| 3 |
| $50.0K |
Zydus Pharmaceuticals USA Inc ranks #8 among 196 Exemestane importers from India. Average shipment value of $50.0K compared to the market average of $26.2K. The closest competitors by value are ACCORD UK and AUROLOGISTICS LLC, (AUROBINDO PHARM.
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 57+ countries, 196+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, supplier contacts, and formulation details for Zydus Pharmaceuticals USA Inc.
Request DemoView Pricing βTrade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Exemestane. For current order-level data, contact TransData Nexus.